Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on World Healthcare Report.
Press releases published on June 9, 2025
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
GlobeNewswire
·
June 9, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a …
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of …
New Report Reveals Canadian Men Are Dying Too Young
GlobeNewswire
·
June 9, 2025
TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Movember – the world’s leading men’s health charity – has released the Real Face of Men’s Health Report (the report) detailing new findings on the state of men’s health in Canada. The report reveals that more than …
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
GlobeNewswire
·
June 9, 2025
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and bifunctional degraders, today announced …
Un nouveau rapport révèle que les hommes canadiens meurent trop jeunes
GlobeNewswire
·
June 9, 2025
TORONTO, 09 juin 2025 (GLOBE NEWSWIRE) -- Movember, le plus important organisme caritatif mondial dédié à la santé masculine, a publié le rapport intitulé Le vrai visage de la santé masculine, qui présente les nouvelles conclusions sur l'état de la santé …
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
GlobeNewswire
·
June 9, 2025
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host …
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter …
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
GlobeNewswire
·
June 9, 2025
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), …
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
GlobeNewswire
·
June 9, 2025
Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and …
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
GlobeNewswire
·
June 9, 2025
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination …
Keros Announces Return of $375 Million in Excess Capital to Stockholders
GlobeNewswire
·
June 9, 2025
LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …
Portage Biotech and Compedica Stock-for-Stock Exchange
GlobeNewswire
·
June 9, 2025
DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings …
Liver Canada delivers a wake-up call to Canada in new PSA
GlobeNewswire
·
June 9, 2025
TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Liver Canada is confronting the silent epidemic of liver disease with a powerful new public service announcement (PSA) titled Wake-Up Call. The campaign seeks to challenge misconceptions and encourage proactive …
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
GlobeNewswire
·
June 9, 2025
Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to …
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
GlobeNewswire
·
June 9, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the …
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans
GlobeNewswire
·
June 9, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'APPROBATION PAR L'EMA DE LA PROLONGATION DE LA DURÉE DE CONSERVATION DE MASIVET® À 4 ANS Paris, 9 juin 2025, 8h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui que l'Agence européenne des …
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
GlobeNewswire
·
June 9, 2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled …
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
GlobeNewswire
·
June 9, 2025
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE Nantes, France, 9 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), informe ses actionnaires et le marché de la mise à jour des modalités de l’Assemblée Générale Mixte …
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
GlobeNewswire
·
June 9, 2025
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025- …
Communiqué de presse : Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS
GlobeNewswire
·
June 9, 2025
Sanofi accélère la livraison mondiale de Beyfortus pour préparer les professionnels de santé plusieurs mois avant la saison 2025-2026 de VRS Paris, le 9 juin 2025. Sanofi livrera Beyfortus (nirsevimab) dès le début du T3 pour assurer une large …